The Program in Systems, Pathways and Targets (SPT) comprises a group of cancer researchers in the basic and clinical sciences who are focused on translating basic science findings in the following areas: (A) Systems, (B) Organs, (C) Pathways and (D) Targets. The goals for this program are to study the dynamic interactions between cancer cells and their environment (systems and organs) with respect to specific types of cancer (organs) and the signaling pathways relevant to these cancers (pathways). The SPT program reflects the emerging view that modeling interactions among dynamic regulatory pathways at varying time and space scales is critical to understanding how these networks drive cancer, and critical for identifying Achilles heels in oncogenesis. The overarching goal is to identify key proteins or points of crosstalk for therapeutic intervention (targets). SPT program members serve as principal investigators on cooperative group, industry, and hypothesis-driven investigator-initiated (HDII) trials and they participate in clinical trials.
|Marian Waterman, Ph.D., co-Leader of the SPT, is Professor and Vice Chair of Microbiology & Molecular Genetics. Dr. Waterman’s area of expertise is Wnt signaling and LEF/TCF regulation in cancer. Models of colon cancer, chronic myelogenous leukemia and breast cancer are active areas of focus.|
|John Lowengrub, Ph.D., co-Leader of the SPT, is a Professor of Mathematics. Dr. Lowengrub has extensive experience in the fields of mathematical and computational biology, applied and computational mathematics, mathematical oncology, complex fluids and materials science. Over the past several years, Dr. Lowengrub has developed multiscale models involving continuum, discrete and hybrid continuum-discrete models of tissue and tumor growth that bridge signaling processes at the subcell scale to tissue-scale models of growth and morphology.|
|David Fruman, Ph.D.,
co-Leader of the SPT is a Professor of Microbiology and Biochemistry.
The focus of research in the Fruman Lab is signal transduction in
lymphocytes and leukemia cells. The long-term goal is to define
signaling components whose function is specific to particular immune
cell types or responses. Dr. Fruman is particularly interested in cells of the immune
system, both normal lymphocytes and their transformed counterparts.